Transgene Biotek Complete Financial Statements

In FY2025, Transgene Biotek (TRABI) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹-0.05 and ROE of -10.0%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see TRABI stock live price.

11 Years of Data
2025 - 2015

Complete Financial Data Export

Profitability Ratios

Operating Margin -675.00% 2025 data
Return on Assets -0.69% 2025 data
Return on Equity -10.00% 2025 data

Balance Sheet Ratios

Current Ratio 0.01 2025 data
Equity Ratio 6.94% 2025 data

TRABI Revenue, Net Profit & EBITDA — Year-on-Year Growth

TRABI YoY (Sept 2024 vs Sept 2025).

Assets Growth
+1.4%
Year-over-Year
Equity Growth
-9.1%
Year-over-Year

TRABI Income Statement — Revenue, EBITDA & Net Profit

Transgene Biotek revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹-0.05 (2025). Explore TRABI Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 Mar 2023 Jun 2023 Dec 2023 Sept 2022 Mar 2022 Jun 2022 Dec 2022 Sept 2021 Mar 2021 Jun 2021 Dec 2021 Sept 2020 Mar 2020 Jun 2020 Dec 2020 Sept 2019 Mar 2019 Jun 2019 Dec 2019 Sept 2018 Jun 2018 Dec 2018
Revenue 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 2
Expenses 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
EBITDA 0 -1 0 0 0 0 0 0 0 0 0 0 -1 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 2
Operating Profit Margin % -160.00% -675.00% -280.00% -120.00% -133.00% -520.00% -820.00% -113.00% -240.00% 0.00% -120.00% -200.00% 0.00% -56.00% -233.00% 0.00% 0.00% -1900.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13.00% 0.00% 0.00% 0.00% 0.00% 0.00% -86.00% -425.00%
Depreciation 0 0 0 0 0 0 0 0 0 1 0 0 1 3 1 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 -1 0 0 0 0 0 0 0 -2 0 0 -2 -3 -1 -1 -3 -3 -3 -3 -3 -3 -3 -3 -3 -1 -3 -3 -3 -3 -1
Tax 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit 0 -1 0 0 0 0 0 0 0 -2 0 0 -2 -3 -1 -1 -3 -3 -3 -3 -3 -3 -3 -3 -3 -1 -3 -3 -3 -3 -1
Earnings Per Share (₹) -0.05 -0.09 -0.06 -0.05 -0.01 -0.04 0.03 -0.01 -0.02 -0.19 -0.02 -0.02 -0.23 -0.34 -0.18 -0.18 -0.34 -0.34 -0.34 -0.35 -0.35 -0.37 -0.35 -0.33 -0.36 -0.10 -0.37 -0.35 -0.35 0.00 -0.12

TRABI Balance Sheet — Assets, Liabilities & Shareholders' Equity

TRABI total assets ₹144 Cr, total equity ₹10 Cr, total liabilities ₹ Cr (2025) — ROE -10.0%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 144 142 142 147 157 167 177 187 198 313 344
Current Assets 1 1 1 1 1 1 1 1 1 4 18
Fixed Assets 8 6 6 11 21 31 41 51 61 141 163
Capital Work in Progress 2 2 2 2 2 2 2 2 2 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0
Other Assets 134 134 134 134 134 134 134 134 135 172 180
LIABILITIES
Total Liabilities
Current Liabilities 121 121 121 121 121 120 120 120 128 127 127
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 10 11 11 17 22 33 44 52 59 174 191
Share Capital 76 76 76 76 76 76 76 76 76 76 76
Reserves & Surplus -66 -65 -64 -58 -54 -43 -32 -23 -17 99 116

TRABI Cash Flow Statement — Operating, Investing & Financing

Transgene Biotek operating cash flow ₹1 Cr, investing ₹-2 Cr, financing ₹1 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 1 0 0 0 0 0 -2 -1 0 7 4
Investing Activities -2 0 0 0 0 0 2 3 0 -7 -5
Financing Activities 1 0 0 0 0 0 0 -2 0 0 1
Net Cash Flow 0 0 0 0 0 0 0 0 0 0 0